[
    "{\"step_by_step_thinking\": \"To determine if Sotrovimab is effective for COVID-19, we need to review the information provided in the relevant documents. Document [0] states that Sotrovimab was granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate COVID-19 in high-risk individuals. Document [5] reports a retrospective analysis that shows Sotrovimab reduced the risk of hospitalization or death in non-hospitalized patients with symptomatic COVID-19. Document [15] describes a phase 3 trial where Sotrovimab significantly reduced the risk of hospitalization or death in non-hospitalized high-risk patients with mild-to-moderate COVID-19. Based on this information, it can be concluded that Sotrovimab is effective for COVID-19.\", \"answer_choice\": \"A. yes\"}"
]